A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix
(MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard
therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC XBiotech, Inc.